Brown Advisory’s Humacyte HUMA Stock Holding History

Brown Advisory’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.96K	Hold	13,129	–	–	﹤0.01%	1391
2025 Q4	$12.6K	Hold	13,129	–	–	﹤0.01%	1379
2025 Q3	$22.8K	Hold	13,129	–	–	﹤0.01%	1375
2025 Q2	$27.4K	Hold	13,129	–	–	﹤0.01%	1348
2025 Q1	$22.4K	Hold	13,129	–	–	﹤0.01%	1318
2024 Q4	$66.3K	Hold	13,129	–	–	﹤0.01%	1322
2024 Q3	$71.4K	Hold	13,129	–	–	﹤0.01%	1244
2024 Q2	$63K	Hold	13,129	–	–	﹤0.01%	1209
2024 Q1	$40.8K	Hold	13,129	–	–	﹤0.01%	1231
2023 Q4	$37.3K	Hold	13,129	–	–	﹤0.01%	1206
2023 Q3	$38.5K	Hold	13,129	–	–	﹤0.01%	1175
2023 Q2	$37.5K	Hold	13,129	–	–	﹤0.01%	1168
2023 Q1	$40.6K	Hold	13,129	–	–	﹤0.01%	1192
2022 Q4	$27.7K	Hold	13,129	–	–	﹤0.01%	1191
2022 Q3	$43K	Hold	13,129	–	–	﹤0.01%	1114
2022 Q2	$42K	Hold	13,129	–	–	﹤0.01%	1086
2022 Q1	$93K	Hold	13,129	–	–	﹤0.01%	1090
2021 Q4	$95K	Hold	13,129	–	–	﹤0.01%	1213
2021 Q3	$152K	Buy	+13,129	New	+$150K	﹤0.01%	1070

Other funds holding HUMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Antipodes Partners Royal Exchange, Australia $5.19B AUM 36.17% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Brown Advisory's HUMA Position: Q1 2026 in Review

Brown Advisory held its Humacyte (HUMA) position steady in Q1 2026 at 13,129 shares worth $7.96K. The position accounts for ﹤0.01% of the portfolio, ranked #1391.

Brown Advisory first reported a position in HUMA in Q3 2021 and has held it in 19 quarters since. The position peaked at $152K in Q3 2021. 158 funds tracked by Wall St. Rank hold HUMA as of Q1 2026.

Brown Advisory held 13,129 shares of Humacyte worth $7.96K as of Q1 2026.
Brown Advisory left its Humacyte share count unchanged in Q1 2026.
Humacyte made up ﹤0.01% of Brown Advisory's portfolio in Q1 2026, its #1391 holding.
Brown Advisory first reported a position in Humacyte in Q3 2021 and has held it in 19 quarters since.
Brown Advisory's Humacyte position peaked at $152K in Q3 2021.
158 funds tracked by Wall St. Rank held Humacyte as of Q1 2026.

Based on Brown Advisory's 13F filing for Q1 2026, filed 15 May 2026.